I
134.47
0.11 (0.08%)
| Previous Close | 134.36 |
| Volume | 1,546,509 |
| Price / Earnings (Forward) | 54.95 |
| Price / Sales | 9.57 |
| Price / Book | 15.03 |
| 52 Weeks Range |
| Profit Margin | 18.29% |
| Operating Margin (TTM) | 15.61% |
| Diluted EPS (TTM) | 5.54 |
| Quarterly Revenue Growth (YOY) | 28.80% |
| Quarterly Earnings Growth (YOY) | -31.30% |
| Total Debt/Equity (MRQ) | 131.40% |
| Current Ratio (MRQ) | 4.47 |
| Operating Cash Flow (TTM) | 406.50 M |
| Levered Free Cash Flow (TTM) | 84.25 M |
| Return on Assets (TTM) | 6.94% |
| Return on Equity (TTM) | 37.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Insulet Corporation | Mixed | Bearish |
AIStockmoo Score
-0.1
| Analyst Consensus | NA |
| Insider Activity | -3.0 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.10 |
|
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.29% |
| % Held by Institutions | 102.56% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HUFFINES ROBERT LUTHER | 130.47 | - | 178 | 23,224 |
| MAZELSKY JONATHAN JAY | 130.47 | - | 141 | 18,396 |
| PEASE FLAVIA | - | 130.79 | -1,882 | -246,147 |
| Aggregate Net Quantity | -1,563 | |||
| Aggregate Net Value ($) | -204,527 | |||
| Aggregate Avg. Buy ($) | 130.47 | |||
| Aggregate Avg. Sell ($) | 130.79 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PEASE FLAVIA | Officer | 01 Oct 2026 | Disposed (-) | 1,882 | 130.79 | 246,147 |
| HUFFINES ROBERT LUTHER | Director | 30 Sep 2026 | Acquired (+) | 178 | 130.47 | 23,224 |
| MAZELSKY JONATHAN JAY | Director | 30 Sep 2026 | Acquired (+) | 141 | 130.47 | 18,396 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |